| [1] |
De Vita V, Hellman S, Rosenberg SA. Cancer: principles and practice of oncology[J]. J Am Med Association, 2001, 286: 1904-1905. DOI: 10.1001/jama.286.15.1904. |
| [2] |
Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stageⅠ and stage Ⅱ epithelial ovarian cancer results of two prospective randomized trials[J]. NEJM, 1990, 322(15): 1021-1027. DOI: 10.1056/NEJM199004123221501. |
| [3] |
Chan JK, Tian C, Monk BJ, et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study[J]. Cancer, 2008, 112(10): 2202-2210. DOI: 10.1002/cncr.23390. |
| [4] |
Colombo N, Guthrie D, Chiari S, et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer[J]. J Natl Cancer Inst, 2003, 95(2): 125-132. DOI: 10.1093/jnci/95.2.125. |
| [5] |
Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial[J]. J Natl Cancer Inst, 2003, 95(2): 113-125. DOI: 10.1093/jnci/95.2.113. |
| [6] |
Lawrie TA, Winter-Roach BA, Heus P, et al. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer[J]. Cochrane Database Syst Rev, 2015, (12): CD004706. DOI: 10.1002/14651858.CD004706.pub5. |
| [7] |
Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase Ⅲ trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma[J]. J Natl Cancer Inst, 2003, 95(2): 105-112. DOI： 10.1093/jnci/95.2.105. |
| [8] |
Tropé C, Kaern J, Hogberg T, et al. Randomized study on adjuvant chemotherapy in stage Ⅰhigh-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument[J]. Ann Oncol, 2000, 11(3): 281-288. DOI: 10.1023/a：1008399414923. |
| [9] |
Bolis G, Colombo N, Pecorelli S, et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P)[J]. Ann Oncol, 1995, 6(9): 887-893. DOI: 10.1093/oxfordjournals.annonc.a059355. |
| [10] |
Collinson F, Qian W, Fossati R, et al. Optimal treatment of early-stage ovarian cancer[J]. Ann Oncol, 2014, 25(6): 1165-1171. DOI: 10.1093/annonc/mdu116. |
| [11] |
Adams G, Zekri J, Wong H, et al. Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy？[J]. BJOG, 2010, 117(12): 1459-1467. DOI: 10.1111/j.1471-0528.2010.02635.x. |
| [12] |
Kolb BA, Buller RE, Connor JP, et al. Effects of early postoperative chemotherapy on wound healing[J]. Obstet Gynecol, 1992, 79(6): 988-992.
|
| [13] |
Wright J, Doan T, McBride R, et al. Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival[J]. Br J Cancer, 2008, 98(7): 1197-1203. DOI: 10.1038/sj.bjc.6604298. |
| [14] |
Tewari KS, Java JJ, Eskander RN, et al. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study[J]. Ann Oncol, 2016, 27(1): 114-121. DOI: 10.1093/annonc/mdv500. |
| [15] |
Dinkelspiel HE, Tergas AI, Zimmerman LA, et al. Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer[J]. Gynecol Oncol, 2015, 137(2): 203-209. DOI: 10.1016/j.ygyno.2015.02.013. |
| [16] |
Chatterjee S, Chen L, Tergas AI, et al. Utilization and outcomes of chemotherapy in women with intermediate-risk, early-stage ovarian cancer[J]. Obste Gynecol, 2016, 127(6): 992-1002. DOI: 10.1097/AOG.0000000000001404. |
| [17] |
Winter-Roach BA, Kitchener HC, Lawrie TA. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer[J]. Cochrane Database Syst Rev, 2012, (3): CD004706. DOI: 10.1002/14651858.CD004706.pub4. |
| [18] |
Hogen L, Brar H, Covens A, et al. Is adjuvant chemotherapy beneficial for surgical stage Ⅰ ovarian clear cell carcinoma？[J]. Gynecol Oncol, 2017, 147(1): 54-60. DOI: 10.1016/j.ygyno.2017.07.128. |
| [19] |
Takada T, Iwase H, Iitsuka C, et al. Adjuvant chemotherapy for stage Ⅰ clear cell carcinoma of the ovary an analysis of fully staged patients[J]. Int J Gynecol Cancer, 2012, 22(4): 573-578. DOI: 10.1097/IGC.0b013e31823fd413. |
| [20] |
Mizuno M, Kajiyama H, Shibata K, et al. Adjuvant chemotherapy for stage Ⅰ ovarian clear cell carcinoma is it necessary for stage Ⅰ A？[J]. Int J Gynecol Cancer, 2012, 22(7): 1143-1149. DOI: 10.1097/IGC.0b013e31825c7cbe. |
| [21] |
Oseledchyk A, Leitao MM Jr, Konner J, et al. Adjuvant chemotherapy in patients with stage Ⅰ endometrioid or clear cell ovarian cancer in the platinum era: a surveillance, epidemiology, and end results cohort study, 2000-2013[J]. Ann Oncol，2017, 28(12): 2985-2993. DOI: 10.1093/annonc/mdx525. |
| [22] |
Timmers PJ, Zwinderman AH, Teodorovic I, et al. Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial[J]. Int J Gynecol Cancer, 2009, 19(1): 88-93. DOI: 10.1111/IGC.0b013e3181991546. |
| [23] |
Nasioudis D, Haggerty AF, Giuntoli RL, et al. Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma[J]. Gynecol Oncol, 2019, 154(2): 302-307. DOI: 10.1016/j.ygyno.2019.05.009. |
| [24] |
Chan JK, Java JJ, Fuh K, et al. The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients: an analysis of NRG Oncology/Gynecologic Oncology Group trials[J]. Gynecol Oncol, 2016, 143(3): 490-495. DOI: 10.1016/j.ygyno.2016.09.015. |
| [25] |
Young RC, Brady MF, Nieberg RK, et al. Adjuvant treatment for early ovarian cancer: a randomized phase Ⅲ trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study[J]. J Clin Oncol, 2003, 21(23): 4350-4355. DOI: 10.1200/JCO.2003.02.154. |
| [26] |
Bell J, Brady MF, Young RC, et al. Randomized phase Ⅲ trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2006, 102(3): 432-439. DOI: 10.1016/j.ygyno.2006.06.013. |
| [27] |
Chan JK, Tian C, Fleming GF, et al. The potential benefit of 6 vs 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2010, 116(3): 301-306. DOI: 10.1016/j.ygyno.2009.10.073. |
| [28] |
FIGO Committee on Gynecologic Oncology, Prat J. FIGO′s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication[J]. J Gynecol Oncol, 2015, 26(2): 87-89. DOI: 10.3802/jgo.2015.26.2.87. |
| [29] |
Deborah K, Ronald D, Jamie N, et al. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer (version 3. 2019)[EB/OL]. (2019-11-26) [2020-01-04].
URL
|
| [30] |
Kleppe M, van der Aa MA, Van Gorp T, et al. The impact of lymph node dissection and adjuvant chemotherapy on survival: a nationwide cohort study of patients with clinical early-stage ovarian cancer[J]. Eur J Cancer, 2016, 66: 83-90. DOI: 10.1016/j.ejca.2016.07.015. |
| [31] |
Matulonis UA, Sood AK, Fallowfield L, et al. Ovarian cancer[J]. Nat Rev Dis Primers, 2016, 2: 16061. DOI: 10.1038/nrdp.2016.61. |
| [32] |
Desantis CE, Siegel RL, Sauer AG, et al. Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities[J]. CA Cancer J Clin, 2016, 66(4): 290-308. DOI: 10.3322/caac.21340. |
| [33] |
Zsiros E, Tanyi J, Balint K, et al. Immunotherapy for ovarian cancer: recent advances and perspectives[J]. Curr Opin Oncol, 2014, 26(5): 492-500. DOI: 10.1097/CCO.0000000000000111，PMID: 25036883. |
| [34] |
|